LAVA Therapeutics N.V. announced that the US FDA has granted orphan drug designation for the company’s CD1d targeted GammabodyTM, LAVA-051, for the treatment of chronic lymphocytic leukemia.
[LAVA Therapeutics N.V.]
7992332
{7992332:BBBBBBBB}
apa
50
1
167866
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
